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R. Hobo,a* C.J. van Marrewijk, L.J. Leurs, R.J.F. Laheij and J. Buth on behalf of the
EUROSTAR collaborators1EUROSTAR Data Registry Centre, Catharina Hospital, Eindhoven, The NetherlandsObjective. The purpose of this study was to assess whether there is a difference in outcome of endovascular repair in patients
with and without intraoperative adjuvant procedures.
Methods. Demographic, anatomic and operative details were assessed in patients undergoing endovascular repair using the
EUROSTAR registry and correlated with morbidity and mortality rates. Three groups of adjuvant procedures: (A)
endovascular, (B) surgical peripheral arterial and (C) surgical abdominal arterial were compared with a group of patients
without an adjuvant procedure (D). Logistic regression and Cox proportional hazards model were used for statistical
analysis.
Results. Of 4631 endovascular repairs, 1353 patients (29.2%) required adjuvant procedures. Additional endovascular
procedures were performed in 1057 (78.1%), surgical peripheral arterial in 193 (14.3%) and surgical abdominal arterial in
103 (7.6%). The 30-day mortality rate was significantly higher in categories with peripheral arterial surgical (6.7%) and
abdominal surgical procedures (7.8%) compared to patients without adjuvant procedures (1.5%, pZ.001 and pZ.004,
respectively). Life-table-analysis demonstrated that late mortality, conversion or rupture rates were not increased in patients
with an adjuvant procedure.
Conclusion. Adjuvant surgical procedures were associated with increased 30-day mortality. Because of this higher risk,
endovascular repair should be recommended with caution when surgical adjuvant procedures are anticipated.Keywords: Endovascular repair; Abdominal aortic aneurysm; Adjuvant procedures.Endovascular stent-grafting is a popular treatment for
abdominal aortic aneurysms (AAA).1–3 Due to
ongoing technical evolution of stent-grafts the indi-
cations for endovascular aneurysm repair (EVAR)
have widened.4 Patients with co-morbidities or com-
plex aneurysm anatomy often require adjuvant pro-
cedures.5–7 Moreover, adjuvant procedures are used to
resolve intraoperative pitfalls.8 Adjuvant procedures
may be performed for gaining access to the aneurysm
in case of tortuous or occluded iliac arteries, for better
anchoring the device in case of imperfect fixation and
for preserving the blood flow to peripheral arteries.
Thus, many patients, who otherwise would be treated
by open repair, can undergo endovascular repair by
employing additional techniques.7,9,10 There are few
reports on the outcome of adjuvant proceduresing author. R. Hobo, MSc, Department of Surgery,
ospital, P.O. Box 1350, 5602 ZA Eindhoven, The
: eurostar@iae.nl
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study was to compare the early and late outcome of
endovascular repair requiring adjuvant procedures
with uncomplicated endovascular therapy.Materials and MethodsDesign
Data was retrieved from the European collaborators
on stent-graft techniques for abdominal aortic aneur-
ysm repair (EUROSTAR) registry.12,13 This multi-
centre voluntary registry was established in 1996
with the objective of collecting and analysing data
from AAA patients undergoing endovascular treat-
ment with commercially available self-expanding
stent-grafts, including Talent (AVE/Medtronic, Sun-
rise, FL, USA), AneuRx (AVE/Medtronic), ZenithEur J Vasc Endovasc Surg 30, 20–28 (2005)
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Adjuvant Procedures 21(William Cook, Bloomington, IN, USA), Excluder
(Gore and associates, Newark, DE, USA), Fortron
(Cordis, Waterloo, Belgium) and Lifepath (Edwards,
Irvine, CA, USA). The operative procedure has been
described in detail previously.14,15 Patients with a non-
ruptured, asymptomatic AAA were selected for
elective endovascular surgery. All patients had read
the patient information and consent was obtained.
Enrollment in the registry was prospective on an
intention-to-treat basis to prevent selection bias.
Patients who were treated before the commencement
of the registry (the retrospective cohort) were excluded
from the analysis. Participating physicians had to
complete a standardised case record form (CRF) for
submitting to the registry centre. Since 2002, patient
data could be entered online into the EUROSTAR
database via the website www.eurostar-online.org
(KIKA Medical, Nancy, France).
Demographic information of the patient, risk
factors according to SVS-ISCVS risk score, aortic
anatomic characteristics assessed by enhanced com-
puter tomography (CT) and angiography, operative
technical and procedural details, mortality, endoleaks,
complications, secondary interventions and ruptures
were recorded. Findings at clinical examination and
CT assessment, angiography, magnetic resonance
imaging (MRI) or duplex ultrasound scanning (DUS)
during follow-up were recorded at 1, 3, 6, 12, 18 and 24
months and annually thereafter. The patient series
analysed in this report was enrolled between October
1996 and November 2003.
Early and late outcome were compared between
patients without (group D) and with intraoperative
adjuvant procedures. The latter category is subdivided
into endovascular (group A), surgical peripheral
arterial, including groin procedures (group B) and
surgical abdominal arterial (group C) adjuvant pro-
cedures. Patients who had more than one adjuvant
procedure were assigned to the group according to
their most invasive intervention. Crossover femoro-
femoral bypasses and occluders in patients with an
aortouniliac stent-graft and endograft extensions were
not regarded as an adjuvant procedure. Patients with a
maximal aneurysm diameter of less than 40 mm (NZ
248), patients with missing operation data (NZ62) and
patients with stent-grafts that are now withdrawn
from the market (NZ1365) were excluded from this
study.Outcome variables
Early complications were divided into device
migration, graft thrombosis, arterial thrombosis,emboli, endoleaks at the completion angiogram,
systemic complications, 30-day conversion, rupture
and mortality. Intraoperative adverse events were not
regarded as outcome measures. Late outcome events
included endoleaks, endograft migration, kinking,
stenosis and thrombosis. Moreover, AAA rupture,
aneurysmal growth (defined as an 8 mm increase from
the preoperative measurement), secondary interven-
tion and all-cause and aneurysm-related mortality
were assessed as outcome events. Aneurysm-related
mortality was defined as death within 30 days of initial
or secondary intervention or associated with rupture
or endograft infection. Reporting was in accordance
with the guidelines of the ad hoc Committee for
Standardized Reporting Practices in Vascular Surgery
of The Society for Vascular Surgery/American Associ-
ation for Vascular Surgery.16Statistical analysis
Univariate chi-square tests and multi-variate logistic
regression analysis were performed to study the
differences in procedural outcome and mortality
between patients with and without adjuvant pro-
cedures. Kaplan–Meier analysis and Cox proportional
hazards model were used to assess the differences in
late outcome and mortality. The results of the
comparisons were expressed as odds ratios (OR) or
hazard rates (HR) with corresponding 95% confidence
interval (CI). Adjustment for patient, anatomic, pro-
cedure and physician factors; including age, gender,
anatomic characteristics, type of stent-graft, year of
procedure and team experience were made. A p value
less than 0.05 was required to achieve statistical
significance. All analyses were performed with the
SAS system (version 8.00, SAS Institute, Cary, NC,
USA).ResultsPatients
In total 4631 patients from 146 centres were included
in the study-group. One thousand three hundred and
fifty-three patients (29.2%) required 1531 adjuvant
procedures (Table 1). These were categorized into
group A, endovascular (1057, 78.1%), group B, surgical
peripheral arterial (193, 14.3%) and group C, surgical
abdominal arterial (103, 7.6%). Percutaneous trans-
luminal angioplasty (PTA) (55.5%) and coil embolisa-
tion (39.7%) were the most frequently performed
endovascular adjuvant procedures. EndarterectomyEur J Vasc Endovasc Surg Vol 30, July 2005
Table 1. Classification of adjuvant procedures
Endovascular
(NZ1154 patients)
N Surgical peripheral
(NZ199 patients)
N Surgical abdominal
(NZ103 patients)
N
PTA/stent for stenosis 681 Patch, E-E anast, fem-distal
bypass, profunda plasty
38 Ilio-femoral bypass for access 43
(Coil-)embolisation of side-
branches
487 Endarterectomy 70 Hypogastric artery bypass/
implantation
9
Brachial artery catheterisation 17 Crossover femoro-femoral
bypass*
47 Decoiling, retroperitoneal
approach for access
2
Plugs, coils common iliac artery 5 CFA aneurysm repair 9 Hypogastric surgical ligation 7
Additional thoracic endografts 7 Thrombectomy, embolectomy,
lysis
9 Common iliac art surgical lig-
ation
6
Hypogastric artery branch
endograft
9 AV-fistula surgical correction 1 Iliac artery repair 1
Miscellaneous endovascular
interventions
22 Other peripheral interventions 25 Ilio-fem/ilio-iliaca crossover 9
Pull down manoeuvre 3
Other surgical abdominal
interventions
24
Total number of procedures 1228 199 104
Note: 1154 patients had 1228 endovascular procedures. One thousand and fifty-seven of them had no surgical adjuvant procedures and were
assigned to group A. From 199 patients with peripheral surgical adjuvant procedures six had also surgical abdominal procedures and were
assigned to group D.
* Crossover femoro-femoral bypass with an aortouniiliac stent was not regarded as an adjuvant procedure.
R. Hobo et al.22(35.2%) and crossover femoro-femoral bypass (23.6%)
were the most frequent surgical peripheral adjuvant
procedures and iliofemoral bypass for access (41.4%)
was the most frequent surgical abdominal adjuvant
procedure. Females required significantly more per-
ipheral surgical adjuvant procedures than males (pZ
.009) (Table 2).Table 2. Patient characteristics and risk factors
Patient character-
istics, NZ4631
patients
Mean (GSD) Endovascular
(group A), NZ1057
Age (years) 71.7 (7.7)
Max aneurysm
diameter
(mm) 58.3 (10.8)
Length of follow-up (months) 15.4 (14.7)
N (%)
Gender Male 995 (94.1)
Female 62 (5.9)
ASA class I 78 (7.5)
II 379 (36.2), pZ.007
III 514 (49.1), pZ.001
IIIC/IV 75 (7.2)
Diabetes 121 (11.5)
Smoking 282 (26.7), pZ.004
Hypertension 652 (61.7)
Hyperlipemia 469 (44.4)
Cardiac risk 644 (60.9)
Carotid risk 192 (18.2)
Renal risk 199 (18.8)
Pulmonary risk 469 (44.4)
Previous laparat-
omy
277 (26.2)
Obesity 238 (22.5), pZ.007
Unfit for open sur-
gery or general
anaesthesia
290 (27.4)
P-values represent significant differences compared to group D.
Eur J Vasc Endovasc Surg Vol 30, July 2005Early outcome
The 30-day mortality was significantly higher in group
B (OR: 3.0, 95% CI: 1.5–6.1, pZ.001) and group C (OR:
4.0, 95% CI: 1.8–9.2, pZ.004) compared to group D
(Table 3). Rupture and conversion rates in the first 30
days were not significantly different betweenSurgical peripheral
(group B), NZ193
Surgical abdominal
(group C), NZ103
Controls (group D),
NZ3278
71.5 (7.9) 71.9 (7.9) 71.5 (7.7)
58.6 (13.3) 59.8 (12.2) 58.2 (10.6)
14.1 (14.3) 11.2 (12.7) 15.4 (15.1)
173 (89.6) 93 (90.3) 3090 (94.3)
20 (10.4), pZ.009 10 (9.7) 188 (5.7)
13 (6.7) 6 (5.9) 267 (8.3)
69 (35.8) 29 (28.7), pZ.012 1328 (41.1)
89 (46.1) 52 (51.5) 1407 (43.5)
22 (11.4), pZ.025 14 (13.9), pZ.012 232 (7.2)
28 (14.5) 14 (13.6) 406 (12.4)
50 (25.9) 22 (21.4) 734 (22.4)
131 (67.9) 66 (64.1) 2085 (63.6)
97 (50.3) 44 (42.7) 1348 (41.1)
125 (64.8) 69 (67.0) 1960 (59.8)
38 (19.7) 21 (20.4) 522 (15.9)
49 (25.4), pZ.020 27 (26.2) 610 (18.6)
105 (54.4), p!.001 57 (55.3), pZ.006 1366 (41.7)
58 (30.1) 34 (33.0) 866 (26.4)
57 (28.6) 31 (30.1) 875 (26.7)
59 (30.6) 49 (47.6), p!.001 803 (24.5)
Fig. 1. Life-table of survival for each type of adjuvant procedure. Follow-up data up to 72 months was available, but the
number of patients at that interval was too low for visualization. AP, adjuvant procedure.
Adjuvant Procedures 23procedural categories. Primary conversion on the first
day was less frequently performed in group A (OR:
0.2, 95% CI: 0.0–0.9, pZ0.037). There was only one
rupture in the first month in the whole study group.
Device migration and graft thrombosis were not
increased in the early postoperative phase in any
adjuvant procedure category. The prevalence of
arterial thrombosis was significantly higher in patients
with endovascular (OR: 3.1, 95% CI: 1.2–7.8, pZ.023)
and surgical peripheral adjuvant procedures (OR: 11.4,
95% CI: 3.8–34.1, p!.001) compared to the control
group. Emboli were observed more frequently in thecategory of surgical peripheral adjuvant procedures
(OR: 4.2, 95% CI: 1.1–16.4, pZ.032) and of surgical
abdominal adjuvant procedures (OR: 6.7, 95% CI: 1.7–
27.3, pZ.005) than in the control group. The incidence
of endoleaks at the completion angiogram, combined
types and specific types, was not increased in any
group. Systemic complications (pZ.011 for group A, pZ
.002 for group B and pZ.011 for group C) correlated
significantly with any adjuvant procedure. In particular,
an increased incidence in hepatobiliary (OR: 16.7, 95%
CI: 2.3–120, pZ.008) and bowel (OR: 6.3, 95% CI: 2.6–
15.1, p!.001) complications in group B were notable.Eur J Vasc Endovasc Surg Vol 30, July 2005
Table 3. Outcome: early adverse events and mortality
Endovascular (group A) Surgical peripheral (group B) Surgical abdominal (group C) Controls
(group D)
N (%) 1057 (22.8) 193 (4.2) 103 (2.2) 3278 (70.8)
Procedural outcome
(early postoperative)
% OR (95% CI) % OR (95% CI) % OR (95% CI) %
Device migration 0.5 – 1.0 – 1.9 – 0.3
Graft thrombosis 1.2 – 1.6 – 1.0 – 0.7
Arterial thrombosis 1.0 3.0 (1.2–7.7),
pZ.023
2.6 11.4 (3.8–34.1),
p!.001
0.0 – 0.3
Emboli’s 0.4 – 1.6 4.2 (1.1–16.4),
pZ.032
2.9 6.7 (1.7–27.3),
pZ.006
0.3
Endoleaks at the com-
pletion angiogram
18.2 – 13.5 – 19.4 – 15.2
Systemic complications 14.7 1.3 (1.1–1.6),
pZ.011
18.7 1.7 (1.1–2.5),
pZ.002
21.4 2.0 (1.2–3.3),
pZ.003
10.7
30-day conversion 0.5 – 2.1 – 2.9 – 1.1
30-day mortality 2.4 – 6.7 3.0 (1.5–6.1),
pZ.001
7.8 4.0 (1.8–9.2),
pZ.001
1.5
Duration Mean
(GSD)
Mean
(GSD)
Mean
(GSD)
Mean
(GSD)
Procedure (min) 148 (59.7) p!.001 181 (78.5) p!.001 224 (101.5) p!.001 121 (46.4)
Hospital stay (days) 5.8 (7.0) – 7.3 (10.8) pZ.027 10.3 (13.2) p!.001 5.6 (6.5)
P-values represent significant differences compared to group D.
R. Hobo et al.24Outcome at follow-up
Life table analysis (Fig. 1) demonstrated a significantly
higher overall mortality in patients with surgical
abdominal adjuvant procedures (HR: 2.0, 95% CI:
1.2–3.6, pZ.012) compared to un-assisted procedures.
However, the late mortality (O30 days) was not
increased (Fig. 2). The aneurysm-related mortality
was increased in patients with surgical peripheral
arterial and in patients with surgical abdominal
adjuvant procedures compared to patients without
adjuvant procedures (pZ.026 and p!.001, respect-
ively). The incidence of secondary interventions
during follow-up (including conversion to open
surgery, femoro-femoral bypass, stent placement),
device-related complications (device migration,
stenosis or thrombosis and kinking), endoleaks (com-
bined and type-specific), rupture and aneurysmal
growth was not increased in any of the groups with
adjuvant procedures (Table 4).Discussion
The relatively high prevalence of adjuvant procedures
(29.2% overall) in this EUROSTAR series is comparable
to other studies.8–10 A higher ASA classification was
predictive of adjuvant procedures. This may be
explained by a higher frequency of adverse anatomic
characteristics in patients with co-morbid factors.
Female gender appeared to be an additional risk factor
for surgical adjuvant procedures. This observation is inEur J Vasc Endovasc Surg Vol 30, July 2005agreement with the findings of Wolf et al.who reported a
higher incidence of arterial reconstructions and access
difficulties because of smaller arteries in women.17
The largest category of adjuvant procedures con-
sisted of endovascular procedures (group A, 78.1%).
This kind of procedure demonstrated a higher
incidence of early complications of arterial and
systemic origin. However, the incidence of major
events, such as mortality, conversion and rupture
was not significantly different. It was of note that
primary conversion to open surgery on the first day
was less frequently observed in patients with adjuvant
transfemoral procedures (group A) compared to
patients without. The commonest cause of primary
conversion is access failure.18 Before the decision is
taken to convert the procedure, quite frequently
endovascular adjuvant procedures are attempted to
overcome the access problem and other pitfalls.
Adjuvant procedures were either planned or unex-
pectedly required to resolve intraoperative compli-
cations. Because of this, it was of no surprise that early
procedural outcome was associated with the group
assignment. We did not consider intraoperative events
in this analysis.
None of the severe late adverse outcomes, such as
mortality, conversion or rupture rate was significantly
increased in the patients with endovascular adjuvant
procedures. Thus, the application of endovascular
adjuvant procedures may be considered as a relatively
safe option. However, previous studies are not all in
agreement with this conclusion. For instance it has
been noted that certain complications such as pelvic
Fig. 2. Life-table of patient survival excluding 30-day mortality relative to different types of adjuvant procedure. AP, adjuvant
procedure.
Adjuvant Procedures 25ischaemia has occurred more frequent after coil
embolisation of a hypogastric artery in patients with
common iliac aneurysms.9,19
Surgical peripheral arterial adjuvant procedures
(group B) were associated with a higher rate of early
perioperative complications than un-assisted cases.
The observed increase in hepatobiliary and bowel
systemic complications in this group of patients
cannot readily be explained. Moreover, a 10-fold
increase in prevalence of postoperative predischarge
arterial thrombosis was observed in this category, a
four-fold increase in peripheral emboli and a six-fold
increase in occlusion of the renal artery. An increasedthrombogenicity may explain the reasons for the
adjuvant procedures as well as the thromboembolic
complications. Moreover, any adjuvant surgical pro-
cedure may cause a systemic response perhaps
resulting in hepatobiliary, bowel and thrombotic
complications. Patients in group C, who underwent
surgical abdominal vascular procedures, often devel-
oped systemic complications, mostly of cardiac and
pulmonary origin. Our findings are in accordance with
those of Lee et al., who assessed the outcome after
retroperitoneal adjunctive procedures.10 These
authors observed an almost two-fold increase in
perioperative complications.Eur J Vasc Endovasc Surg Vol 30, July 2005
Table 4. Outcome: late adverse events and mortality
Endovascular (group A) Surgical peripheral (group B) Surgical abdominal (group C) Controls
(group D)
N (%) 1057 (22.8) 193 (4.2) 103 (2.2) 3278 (70.8)
Late postoperative outcome (4 years) % HR (95% CI) % HR (95% CI) % HR (95% CI) %
Device migration 19.0 – 21.3 – 5.9 – 10.8
Stenosis/thrombosis 4.9 – 3.8 – 11.8 – 5.4
Kinking 3.7 – 5.6 – 0.0 – 2.9
Endoleaks 26.6 – 27.0 – 16.9 – 27.0
Rupture 2.0 – 3.6 – 0.0 – 1.2
Secondary intervention
transfemoral
16.4 – 7.8 – 3.7 – 10.1
Secondary femoro-femoral bypass 1.9 – 2.8 – 0.0 – 1.1
Late conversion (O30 days) 7.2 – 6.5 – 1.5 – 3.7
Mortality (4 years)
Overall 20.0 – 20.3 – 24.6 2.0 (1.2–3.6), pZ.012 16.8
Late (O30 days) 18.1 – 14.4 – 18.1 – 15.6
AAA-related 5.7 – 8.8 2.2 (1.2–4.1), pZ.017 14.1 3.1 (1.5–6.6), p!.001 2.9
P-values represent significant differences compared to group D.
R. Hobo et al.26Most importantly, the 30-day mortality rate was
significant higher in surgical peripheral and abdomi-
nal adjuvant procedures than in patients who did not
require adjuvant procedures. This rate of 6.7 and 7.8%,
respectively, is comparable with the mortality rate for
conventional open repair found in other studies.20–24
This underscores the risks of endovascular repair
when it is performed in patients with an unfavourable
anatomy. It may be hypothesized that endovascular
therapy is not a good substitute for open repair in
patients at high risk for a surgical adjuvant procedure.
Conversion to open repair is associated with a higher
operative mortality than initial elective open repair.18
A recent publication recommended open repair in
patients at high anatomic and low physical risk, while
in patients at high anatomic and high medical risk
endovascular repair with adjunct procedures to over-
come these anatomic difficulties is recommended.7
However, after the 30-day postoperative period, no
increased incidence is expected in any of the studied
adverse events, including mortality. The aneurysm-
related mortality is increased, however, this increase is
mainly caused by the increased 30-day mortality rate
rather than by late deaths. From the present study we
may conclude that when surgical adjuvant procedures
can be performed with acceptable initial morbidity
and mortality, long term mortality is not increased.
Caution is warranted when using a registry. The
risk of selection bias in the different study groups may
influence the comparisons. There was a moderate
discrepancy in the distribution of patient character-
istics between groups. However, there is no reason to
assume that the study findings are not valid, as the
calculated odds ratios have been adjusted for these
characteristics and preoperative measurements. The
main selection bias may be that the use of adjuvantEur J Vasc Endovasc Surg Vol 30, July 2005procedures allows endovascular surgery for aneur-
ysms with a more complex anatomy and a widening of
indications.9,10 Multi-centre studies generally report
less favorable results than single-centre investi-
gations.22 Therefore, an underestimation of the mor-
tality rate is less likely than an overestimation.
In conclusion, in the long term no adjuvant
procedure was associated with an increased incidence
of adverse events. Endovascular repair might not be
recommended in patients expected to require surgical
adjuvant procedures because of the increased 30-day
mortality. However, endovascular adjuvant pro-
cedures may be regarded as low risk.Acknowledgements
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